Buckley Capital Advisors’s Soleno Therapeutics SLNO Stock Holding History

Buckley Capital Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-181,750	Closed	-$6.08M	–	19
2026 Q1	$6.08M	Buy	181,750 +32,600	+22%	+$1.28M	4.37%	9
2025 Q4	$6.91M	Buy	+149,150	New	+$8.18M	4.86%	8

Buckley Capital Advisors's SLNO Position: Q2 2026 in Review

Buckley Capital Advisors sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 181,750 shares — an estimated $6.08M sold.

Buckley Capital Advisors first reported a position in SLNO in Q4 2025 and held it in 2 quarters. The position peaked at $6.91M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Buckley Capital Advisors reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Buckley Capital Advisors sold 181,750 Soleno Therapeutics shares in Q2 2026, an estimated $6.08M.
Buckley Capital Advisors first reported a position in Soleno Therapeutics in Q4 2025 and held it in 2 quarters.
Buckley Capital Advisors's Soleno Therapeutics position peaked at $6.91M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Buckley Capital Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.